中国中西医结合外科杂志2018，Vol.24Issue(2)：131-134,4.DOI:10.3969/j.issn.1007-6948.2018.02.001
生白合剂对肺癌化疗后骨髓抑制的疗效观察
Clinical Observation of Shengbai Oral Solution on Prevention of Neutropenia Induced by Chemotherapy for Lung Cancers
摘要
Abstract
Abstact: Objective To observe the effect of Shengbai oral solution on protection of neueropemia induced by chemotherapy of lung cancer. Methods Total 191 patients of advanced lung cancer treated with platinum-containing chemotherapy regimen (dose of chemotherapy: paclitaxel liposome, 175 mg/m2; etoposide, 120 mg/m2or 100 mg/m2; cisplatin, 75 mg/m2; carboplatin, AUC=6) were randomized into two groups. Treatment group (95 patients) administered with Shengbai oral solution, 40 mL three times a day continued 3 days then decreased dose to 20ml continued 3 days, beginning in the first day after chemotherapy. Blood routines were tested every three days. Control group (96 patients) did not use Shengbai oral solution after chemotherapy. The myelosuppression level and the quantity of granulocytic colony stimulating factor (G-CSF) being used were investigated. Results The rate of Ⅲ and Ⅳ myelosuppression was 8.42% in treatment group, which was significant lower than in control group of 23.5 %( χ2=8.52, P<0.01).The quantity of use of G-CSF in treatment group was also significant lower than that in control group (t=3.566, P<0.01). Conclusion Shengbai oral solution can decrease bone marrow suppression caused by chemotherapy in lung cancer patients, reduce the using amount of G-CSF.关键词
生白合剂/肺癌/化疗/顺铂/骨髓抑制Key words
Shengbai Oral Solution/lung cancer/chemotherapy/cisplatin/myelosuppression分类
医药卫生引用本文复制引用
周春花,杨农,陈功,曾亮,杨海燕,刘利,蒋文娟,熊益,郭娜,张永昌..生白合剂对肺癌化疗后骨髓抑制的疗效观察[J].中国中西医结合外科杂志,2018,24(2):131-134,4.基金项目
国家自然科学基金(81401902,81501992) （81401902,81501992）
湖南省自然科学基金(2014JJ2144,2015JJ3086,2015JJ6064,2015JJ6065,2014SK3237,2015JJ3085) （2014JJ2144,2015JJ3086,2015JJ6064,2015JJ6065,2014SK3237,2015JJ3085）
